These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 7369119)
1. FDA to revise drug review process. Welsh JS Am Pharm; 1980 Jan; NS20(1):45. PubMed ID: 7369119 [No Abstract] [Full Text] [Related]
2. Assignment of agency component for review of premarket applications--FDA. Final rule. Fed Regist; 1991 Nov; 56(225):58754-8. PubMed ID: 10115697 [TBL] [Abstract][Full Text] [Related]
3. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach. Miller HI; Young FE Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844 [No Abstract] [Full Text] [Related]
4. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson. Woodcock J Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087 [TBL] [Abstract][Full Text] [Related]
5. How are drugs approved? Part 3. The stages of drug development. Howland RH J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270 [TBL] [Abstract][Full Text] [Related]
6. New office and new leader aim to streamline FDA cancer drug review process. Twombly R J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036 [No Abstract] [Full Text] [Related]
7. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration. Feinsod M; Chambers WA Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539 [TBL] [Abstract][Full Text] [Related]
8. FDA tightens human oversight. Dove A Nat Med; 2001 Jun; 7(6):646. PubMed ID: 11385485 [No Abstract] [Full Text] [Related]
9. Speeding help and hope to the desperately ill. Young FE FDA Consum; 1989 Feb; 23(1):8-9. PubMed ID: 10312854 [No Abstract] [Full Text] [Related]
10. Prospects for reform of the IND/NDA processes: Part I. Romansky MA J Clin Psychopharmacol; 1982 Oct; 2(5):358-61. PubMed ID: 6752215 [No Abstract] [Full Text] [Related]
11. Disease, drugs, and delay: suggested changes for the FDA. Petricciani JC Clin Res; 1990 Dec; 38(4):701-3. PubMed ID: 2276258 [No Abstract] [Full Text] [Related]
12. Group makes recommendations to speed FDA device approvals. Scott L Mod Healthc; 1993 May; 23(19):23. PubMed ID: 10125877 [No Abstract] [Full Text] [Related]
13. FDA insists on more women in drug trials. Josefson D BMJ; 1997 Oct; 315(7112):833. PubMed ID: 9353497 [No Abstract] [Full Text] [Related]
14. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
15. The process of drug decision making: perspectives of an FDA Commissioner. Hayes AH Hosp Formul; 1985 Aug; 20(8):896-900. PubMed ID: 10272396 [TBL] [Abstract][Full Text] [Related]
18. FDA and EMEA pool scientific advice. Katsnelson A Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642 [No Abstract] [Full Text] [Related]
19. FDA user fee plan gets some support from drug makers. Weissenstein E Mod Healthc; 1992 Aug; 22(33):20. PubMed ID: 10119804 [No Abstract] [Full Text] [Related]